View Cart  

Bipartisan Bill Would Extend Exclusivity, Speed Review of Some Combo Drugs

New fixed-dose drug combinations that include at least two INDs and target a serious or life-threatening disease could be eligible for an additional six months of marketing exclusivity and priority review under a new bipartisan-supported bill sponsored by Rep. Brian Bilbray (R-Calif.).

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00